- Home
- PFL vs AQST Comparison
PFL vs AQST Comparison
Compare PFL & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFL
- AQST
- Stock Information
- Founded
- PFL 2003
- AQST 2004
- Country
- PFL United States
- AQST United States
- Employees
- PFL N/A
- AQST N/A
- Industry
- PFL Finance Companies
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- PFL Finance
- AQST Health Care
- Exchange
- PFL Nasdaq
- AQST Nasdaq
- Market Cap
- PFL 333.6M
- AQST 274.4M
- IPO Year
- PFL N/A
- AQST 2018
- Fundamental
- Price
- PFL $8.58
- AQST $3.04
- Analyst Decision
- PFL
- AQST Strong Buy
- Analyst Count
- PFL 0
- AQST 6
- Target Price
- PFL N/A
- AQST $11.17
- AVG Volume (30 Days)
- PFL 113.7K
- AQST 1.4M
- Earning Date
- PFL 01-01-0001
- AQST 05-06-2025
- Dividend Yield
- PFL 11.53%
- AQST N/A
- EPS Growth
- PFL N/A
- AQST N/A
- EPS
- PFL N/A
- AQST N/A
- Revenue
- PFL N/A
- AQST $57,561,000.00
- Revenue This Year
- PFL N/A
- AQST N/A
- Revenue Next Year
- PFL N/A
- AQST $39.51
- P/E Ratio
- PFL N/A
- AQST N/A
- Revenue Growth
- PFL N/A
- AQST 13.79
- 52 Week Low
- PFL $6.98
- AQST $2.24
- 52 Week High
- PFL $8.62
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- PFL 56.06
- AQST 51.97
- Support Level
- PFL $8.51
- AQST $3.05
- Resistance Level
- PFL $8.60
- AQST $3.24
- Average True Range (ATR)
- PFL 0.04
- AQST 0.19
- MACD
- PFL 0.01
- AQST 0.01
- Stochastic Oscillator
- PFL 86.11
- AQST 48.53
About PFL PIMCO Income Strategy Fund Shares of Beneficial Interest
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.